KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $296.0 million.

  • Teva Pharmaceutical Industries' Non-Current Deferred Tax Liability fell 3871.64% to $296.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $296.0 million, marking a year-over-year decrease of 3871.64%. This contributed to the annual value of $296.0 million for FY2025, which is 3871.64% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Non-Current Deferred Tax Liability of $296.0 million as of Q4 2025, which was down 3871.64% from $399.0 million recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Non-Current Deferred Tax Liability peaked at $991.0 million during Q1 2021, and registered a low of $296.0 million during Q4 2025.
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $546.0 million (2022), whereas its average is $591.9 million.
  • In the last 5 years, Teva Pharmaceutical Industries' Non-Current Deferred Tax Liability plummeted by 4472.53% in 2022 and then skyrocketed by 1058.39% in 2023.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Non-Current Deferred Tax Liability stood at $784.0 million in 2021, then plummeted by 30.1% to $548.0 million in 2022, then increased by 10.58% to $606.0 million in 2023, then dropped by 20.3% to $483.0 million in 2024, then plummeted by 38.72% to $296.0 million in 2025.
  • Its Non-Current Deferred Tax Liability stands at $296.0 million for Q4 2025, versus $399.0 million for Q3 2025 and $440.0 million for Q2 2025.